Shijiazhuang Pharma Group: Has received a $25 million R&D milestone payment from AstraZeneca

Shiyao Group announced that it received a $25 million research and development milestone payment from AstraZeneca on July 10, 2026. Previously, the company received the first payment under the agreement on May 29, 2026. The agreement is intended to develop innovative long-acting polypeptide drugs by leveraging Shiyao Group’s long-acting delivery technology platform and its polypeptide drug AI discovery platform.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned